Comprehensive Monograph and Strategic Analysis of VG161: A Multi-Armed Oncolytic Virotherapy for Treatment-Refractory Malignancies

1.0 Executive Summary

VG161 is a next-generation, investigational oncolytic virus therapy engineered from an attenuated Herpes Simplex Virus type 1 (HSV-1) backbone.[1] Developed by Virogin Biotech utilizing its proprietary Synerlytic™ Platform, VG161 represents a significant advancement in the field of immuno-oncology.[1] As a biotech therapeutic, it is currently undergoing extensive clinical evaluation for the treatment of multiple advanced and treatment-refractory solid tumors, including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and various sarcomas.[3]

The therapeutic rationale for VG161 is founded on a sophisticated dual mechanism of action that combines direct, selective lysis of cancer cells with a potent, multi-pronged stimulation of the host's anti-tumor immune response. This is achieved through the viral vector's engineered expression of four synergistic immunomodulatory payloads: interleukin-12 (IL-12), interleukin-15 complexed with its receptor alpha subunit (IL-15/IL-15Rα), and a novel peptide that blocks the programmed cell death-ligand 1 (PD-L1) immune checkpoint.[2] This design aims to not only destroy tumor cells directly but also to fundamentally remodel the tumor microenvironment (TME), transforming immunologically "cold" tumors into "hot," T-cell-infiltrated lesions capable of eliciting a durable, systemic anti-cancer effect.[5]

Clinical data, particularly from the landmark Phase I trial (NCT04806464) in a heavily pre-treated population of patients with advanced HCC, have been highly encouraging. In this salvage setting, VG161 monotherapy demonstrated an Objective Response Rate (ORR) of approximately 17-19% and a Disease Control Rate (DCR) of 60-65%.[8] More importantly, it achieved a median Overall Survival (OS) of 9.4 months, a clinically meaningful outcome for this patient population.[9] The most compelling finding from this trial is the profound survival benefit observed in patients who had previously responded to but later progressed on systemic checkpoint inhibitors (CPIs). This subgroup experienced a median OS of 17.3 months, compared to just 7.4 months for those with primary resistance to CPIs, strongly suggesting that VG161 can reverse acquired immunotherapy resistance.[9] Promising early signals have also been observed in advanced sarcoma, where treatment resulted in prolonged Progression-Free Survival (PFS).[10]

Across all clinical studies to date, VG161 has exhibited a favorable and manageable safety profile. The most frequently reported treatment-related adverse event is fever, which is typically low-grade and resolves with symptomatic care.[9] Critically, no dose-limiting toxicities (DLTs) have been observed, underscoring a wide therapeutic window.[13] This strong clinical profile has been recognized by global regulatory agencies, with VG161 receiving Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA) for HCC and ICC, respectively, as well as a Breakthrough Therapy Designation from China's National Medical Products Administration (NMPA) for advanced HCC.[15]

Strategically, VG161 is positioned as a promising therapeutic agent capable of addressing significant unmet medical needs in multiple hard-to-treat cancers. Its unique ability to re-sensitize tumors to immunotherapy positions it as a potential cornerstone of treatment sequencing, particularly for patients who have exhausted standard CPI options. As a leading candidate in the rapidly expanding oncolytic virus market, VG161's continued development holds the potential to offer a new therapeutic paradigm for patients with advanced malignancies.

2.0 Scientific Foundation and Advanced Mechanism of Action

The therapeutic potential of VG161 is rooted in a sophisticated bioengineering strategy that leverages a viral backbone for tumor-selective cytotoxicity while simultaneously delivering a combination of potent immunomodulatory agents directly to the site of disease. This multi-faceted approach is designed to overcome the complex immunosuppressive barriers that typify advanced solid tumors.

2.1 The Synerlytic™ Platform: Engineering a Next-Generation Oncolytic Virus

VG161 is the pioneering product developed from Virogin Biotech's proprietary Synerlytic™ Platform, which focuses on creating multi-armed oncolytic viruses for cancer therapy.[1]

The HSV-1 Backbone

The choice of Herpes Simplex Virus type 1 (HSV-1) as the viral vector is strategic. HSV-1 is a large, double-stranded DNA virus with several inherent advantages for oncolytic virotherapy. It possesses a natural tropism for a wide range of cell types, including many cancer cells, and has a large genomic capacity, allowing for the insertion of multiple therapeutic transgenes, or "payloads," without compromising its ability to replicate.[16] Its lytic replication cycle naturally leads to the destruction of infected cells, a process that is fundamental to its direct anti-tumor effect.

Safety Engineering via ICP34.5 Gene Deletion

A critical modification to the wild-type HSV-1 virus to create VG161 is the deletion of both copies of the infected cell protein 34.5 (ICP34.5) gene.[1] The

ICP34.5 gene is a primary neurovirulence factor in HSV-1, enabling the virus to replicate within healthy neurons. Its deletion renders the virus highly attenuated, significantly mitigating the risk of neurotoxicity.[1] Furthermore, this deletion provides a mechanism for tumor selectivity. Healthy cells, when infected by a virus, typically shut down protein synthesis as a defense mechanism through the protein kinase R (PKR) pathway. The

ICP34.5 protein normally counteracts this defense. In many cancer cells, however, the PKR pathway is defective, allowing an ICP34.5-deleted virus like VG161 to replicate efficiently and selectively within the tumor while being cleared from surrounding healthy tissues.[5] This engineering step is a cornerstone of ensuring the safety of HSV-1-based oncolytic virotherapies.

2.2 A Multi-Pronged Immunostimulatory Payload: The "Four-in-One" Design

Beyond its inherent oncolytic properties, the defining feature of VG161 is its armament of four distinct, synergistic immunomodulatory payloads designed to orchestrate a robust anti-tumor immune response.[5] This design represents a significant evolution from first-generation oncolytic viruses, which often carried a single, less potent immunostimulant. The selection of these specific payloads reflects a deep understanding of the cancer-immunity cycle, with each component chosen to address a distinct bottleneck that often limits the efficacy of immunotherapy.

IL-12: The Th1 Polarization Signal

Interleukin-12 (IL-12) is a powerful pro-inflammatory cytokine that acts as a master regulator of cell-mediated immunity.[5] When expressed locally by VG161-infected tumor cells, IL-12 serves several critical functions. It promotes the differentiation of naive T-helper cells into a Type 1 helper (Th1) phenotype, which is essential for orchestrating an effective anti-cancer response. It also potently enhances the cytotoxic activity of both cytotoxic T-lymphocytes (CTLs) and Natural Killer (NK) cells, the primary effector cells responsible for killing tumor cells.[6] Finally, IL-12 stimulates the production of interferon-gamma (IFN-

γ), a key cytokine that further amplifies the immune response and can increase the expression of MHC class I molecules on cancer cells, making them more visible to CTLs.[6] Systemic administration of IL-12 has historically been limited by severe toxicity; by producing it directly within the TME, VG161 aims to harness its potent anti-tumor effects while minimizing systemic side effects.

IL-15 and IL-15Rα: Sustaining the T-cell and NK Cell Response

Interleukin-15 (IL-15) is another critical cytokine that supports the proliferation, survival, and activation of key immune effector cells, particularly memory T cells and NK cells.[5] Its inclusion in the VG161 payload is designed to sustain and expand the pool of anti-tumor lymphocytes initiated by IL-12. Virogin's design incorporates a sophisticated enhancement by co-expressing IL-15 with its high-affinity receptor alpha subunit (IL-15Rα). This complexation is known to dramatically increase the stability and biological half-life of IL-15, leading to more potent and sustained signaling.[6] This ensures a durable stimulation of the anti-tumor immune cell populations within the TME, promoting long-term immune memory.

The PD-L1 Blocking Peptide (TF-Fc): Localized Checkpoint Inhibition

To counteract a common tumor escape mechanism, VG161 is armed with a unique payload that functions as an immune checkpoint inhibitor. This payload is a fusion protein (termed TF-Fc) that includes a peptide designed to bind to and block PD-L1.[5] The PD-1/PD-L1 axis is a major pathway used by cancer cells to induce T-cell exhaustion and evade immune destruction. By producing this blocking peptide locally, VG161 aims to "release the brakes" on the newly activated T-cells within the TME, preventing their inactivation and restoring their tumor-killing capacity.[6] This approach of localized checkpoint blockade is a key differentiator from systemic antibody-based CPIs. It concentrates the therapeutic effect where it is most needed, potentially maximizing efficacy while avoiding the systemic immune-related adverse events associated with monoclonal antibody therapies. The fusion to an IgG4 Fc fragment likely enhances the peptide's stability and retention within the tumor.[13]

2.3 Integrated Mechanism: A Synergistic Cascade from Oncolysis to Systemic Immunity

The four payloads and the viral backbone of VG161 do not act in isolation; they initiate a coordinated and self-amplifying therapeutic cascade that progresses from local tumor destruction to systemic, durable anti-cancer immunity.

Phase 1: Direct Oncolysis and Antigen Release

The therapeutic process begins with the intratumoral administration of VG161. The virus selectively infects and replicates within cancer cells, leading to their lytic destruction.[6] This oncolysis serves a dual purpose. First, it directly reduces the tumor burden at the site of injection. Second, and perhaps more importantly, the bursting of cancer cells releases a rich milieu of tumor-associated antigens (TAAs), neoantigens (unique antigens arising from tumor mutations), and danger-associated molecular patterns (DAMPs) into the TME.[5] This release of antigenic material effectively serves as an

in situ personalized cancer vaccine, providing the raw material for the immune system to learn to recognize the cancer.

Phase 2: Remodeling the TME - The "Cold-to-Hot" Transition

The released antigens and DAMPs, in concert with the locally produced IL-12 and IL-15 payloads, trigger a profound remodeling of the TME. This process is often described as transforming an immunologically "cold" (non-inflamed, T-cell-excluded) tumor into a "hot" (inflamed, T-cell-infiltrated) lesion.[5] The DAMPs and cytokines recruit and activate innate immune cells, such as dendritic cells (DCs) and NK cells. The DCs take up the released tumor antigens and migrate to nearby lymph nodes to present them to naive T-cells, priming a tumor-specific adaptive immune response.[15] The newly activated, tumor-specific CTLs then traffic back to the tumor, which is now a cytokine-rich environment highly conducive to their function.

Phase 3: Induction of Abscopal Effects and Systemic Anti-Tumor Immunity

The ultimate goal of this localized therapy is the generation of a powerful and lasting systemic anti-tumor immune response. The primed CTLs, whose function is protected from exhaustion by the local PD-L1 blockade, are not confined to the injected tumor. They can enter the systemic circulation, patrol the body, and recognize and eliminate cancer cells at distant, non-injected metastatic sites.[7] This phenomenon is known as the abscopal effect. Clinical evidence from the Phase I trial of VG161 provided direct support for this mechanism, as some patients exhibited more pronounced regression in non-injected lesions than in the directly treated sites, a hallmark of a systemic immunologic effect.[5] This ability to convert a local treatment into a systemic therapy is what distinguishes next-generation oncolytic viruses like VG161 from purely ablative or locoregional treatments.

3.0 The VG161 Clinical Development Program

Virogin Biotech has orchestrated a comprehensive and ambitious global clinical development program for VG161, designed to evaluate its safety and efficacy across multiple cancer types and in both monotherapy and combination settings. This strategy reflects confidence in the broad applicability of its mechanism of action and aims to establish its role in the modern oncology treatment armamentarium.

3.1 Overview of Global Clinical Strategy

The clinical strategy for VG161 is characterized by its global reach, strategic collaborations, and a multi-pronged approach to indication selection.

The program has a significant international footprint, with clinical trials being conducted in key pharmaceutical markets including the United States, Australia, and China.[2] This global approach not only accelerates patient recruitment but also generates data relevant to diverse regulatory bodies, paving the way for worldwide marketing applications.

A cornerstone of this strategy is the formation of key partnerships. In a pivotal move for market access, Virogin Biotech has partnered with CNBG-Virogin, a joint venture, granting it exclusive rights for the clinical development and commercialization of VG161 in the Greater China region.[4] This collaboration leverages local expertise for navigating the regulatory landscape and market in China, while Virogin retains rights for the rest of the world. In the United States, a strategic research and development collaboration with the renowned MD Anderson Cancer Center serves to accelerate clinical development and provides access to world-class clinical trial infrastructure and expertise.[21]

Virogin is pursuing a broad indication strategy, investigating VG161 in a range of solid tumors known for their challenging, often immune-suppressive microenvironments. The lead indications are primary liver cancers—hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC)—but the program has expanded to include advanced bone and soft tissue sarcomas and gastric cancer.[1] This platform approach is designed to test the hypothesis that VG161's mechanism of TME remodeling can be effective across different histologies.

The clinical program wisely incorporates both monotherapy and combination therapy trials. Initial Phase I studies focused on VG161 as a single agent to establish its intrinsic safety, tolerability, and anti-tumor activity.[2] Building on these findings, subsequent trials have been designed to evaluate VG161 in combination with established immune checkpoint inhibitors, such as the PD-1 antibodies nivolumab and camrelizumab.[12] This dual approach is essential for defining VG161's potential both as a standalone therapy and as a synergistic partner to the current standard of care in immuno-oncology.

Table 1: Comprehensive Summary of VG161 Clinical Trials

The following table provides a consolidated overview of the key clinical trials that constitute the VG161 global development program, summarizing their design, status, and objectives.

Trial Identifier(s)	Phase	Status	Indication(s)	Intervention(s)	Location(s)	Source Snippet(s)
NCT04806464, CTR20202562, NCT04758897	Phase 1	Completed	Advanced Solid Tumors, Primary Liver Cancers (HCC)	VG161 Monotherapy	China	2
NCT05223816, VG161-A201	Phase 2a/2b	Closed to Enrollment	Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (ICC)	VG161 Monotherapy and in combination with Nivolumab	US (Mayo Clinic)	2
ACTRN12620000244909, VG161-A101	Phase 1	Completed	Advanced Solid Tumors	VG161 Monotherapy	Australia	2
CTR20210139, VG161-C102	Phase 1	Ongoing	Primary Liver Cancers	VG161 Monotherapy	China	2
CTR20213020, VG161-C201	Phase 2	Ongoing	Intrahepatic Cholangiocarcinoma (ICC)	VG161 Monotherapy	China	2
NCT06126510, CTR20231564, VG161-C206	Phase 2	Recruiting	Advanced Bone and Soft Tissue Sarcoma	VG161 Monotherapy	China	2
Unspecified ID	Phase 1b/2a	Ongoing	Advanced Primary HCC	VG161 + Camrelizumab	China	12
Unspecified ID	Phase 1b/2a	Ongoing	Advanced Metastatic Gastric Cancer	VG161 + Nivolumab	China	37

4.0 In-Depth Clinical Analysis: Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC)

The clinical development of VG161 has been most advanced in primary liver cancers, where it has demonstrated a compelling profile in a patient population with grim prognoses and limited therapeutic options.

4.1 The Therapeutic Landscape and Unmet Need in Advanced Liver Cancer

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and a leading cause of cancer-related mortality worldwide.[16] The treatment paradigm for advanced, unresectable HCC has been revolutionized in recent years. The current first-line standard of care for most eligible patients is combination immunotherapy, primarily atezolizumab (a PD-L1 inhibitor) plus bevacizumab (a VEGF inhibitor), or the dual checkpoint inhibitor combination of durvalumab (PD-L1) plus tremelimumab (CTLA-4).[24] For patients with contraindications to these regimens, tyrosine kinase inhibitors (TKIs) such as sorafenib or lenvatinib remain first-line options.[27]

Despite these advances, a significant unmet medical need persists. Many patients eventually experience disease progression on first-line immunotherapy, and the therapeutic landscape for second-line treatment and beyond is poorly defined, with no universally accepted standard of care.[2] Outcomes in this setting are dismal, with a 5-year survival rate for patients with distant metastatic disease estimated at a mere 3.5%.[2] This creates a critical need for novel therapies that can provide meaningful clinical benefit after the failure of modern immunotherapy combinations.

Intrahepatic cholangiocarcinoma (ICC), the second most common primary liver cancer, presents a similar challenge.[28] The first-line standard of care for advanced disease is typically gemcitabine and cisplatin chemotherapy, often combined with the PD-L1 inhibitor durvalumab.[29] While targeted therapies are available for the subset of patients with specific molecular alterations (e.g., IDH1 mutations, FGFR2 fusions), the majority of patients lack these actionable targets and face a poor prognosis after first-line therapy fails.[29]

4.2 Landmark Phase I Trial (NCT04806464) in Refractory Liver Cancer

The multicenter Phase I trial (NCT04806464) conducted in China provided the first and most definitive clinical proof-of-concept for VG161. The trial's design included a dose-escalation phase (Part A) followed by a dose-expansion phase (Part B).[9] Its true significance lies in the patient population enrolled: these were individuals with advanced primary liver cancer who were refractory to standard therapies, representing a true salvage setting.[9] The cohort was heavily pre-treated, with 92.5% of patients having received two or more prior lines of systemic therapy and 85% having been treated with checkpoint inhibitors for over three months.[8] The robust results generated in this difficult-to-treat population are therefore particularly noteworthy.

Efficacy Analysis

The efficacy analysis, focusing on the 40 HCC patients included in the study and published in Nature and presented at the 2024 ASCO Annual Meeting, revealed compelling anti-tumor activity for VG161 monotherapy.[8]

• Objective Response and Disease Control: The Objective Response Rate (ORR), defined by tumor shrinkage per RECIST 1.1 criteria, was reported between 17.14% (6 of 35 evaluable patients) and 18.92% (in a cohort of 37 patients).[8] The Disease Control Rate (DCR), which includes patients with stable disease in addition to responses, was between 60.00% and 64.86%.[8] These rates are clinically significant in a third-line or later setting.
• Survival Outcomes: The median Progression-Free Survival (PFS) was 2.90 months (95% CI: 1.85-3.95).[9] The median Overall Survival (OS) for the entire cohort was 9.40 months (95% CI: 0.47-18.33), with one report citing a median OS of 12.4 months in a slightly different patient cut.[8] This survival duration is highly favorable when compared to historical outcomes for third-line therapies in HCC.

The most profound finding of the trial, however, emerged from a subgroup analysis based on patients' prior experience with checkpoint inhibitors. The results strongly indicate that VG161 is not merely another cytotoxic agent but functions as a biological modifier capable of reversing acquired immunotherapy resistance. Patients who had previously shown some sensitivity to CPIs (defined as treatment for >3 months before progression) derived a dramatically greater survival benefit from VG161 than those with primary resistance (treatment for ≤3 months). The median OS in the prior-responder group was 17.3 months, compared to just 7.4 months in the primary-resistance group (HR: 0.32, p<0.05).[9]

Furthermore, the study revealed that VG161 treatment could re-sensitize patients' tumors to subsequent therapies. Patients who were able to receive further anti-cancer treatment (such as TKIs or CPIs) after progressing on VG161 survived significantly longer than those who did not, achieving a median OS of 20.1 months versus 8.8 months (HR: 0.30, p<0.05).[9] This suggests that VG161 remodels the TME in such a way that it restores susceptibility to drugs that had previously failed. This positions VG161 not just as a standalone treatment, but as a crucial "bridge" therapy that could unlock further lines of treatment for patients who would otherwise have no options.

Another pivotal discovery from the trial was the identification of a predictive gene signature. Through RNA sequencing of pre-treatment tumor samples, researchers identified a unique gene expression pattern that successfully predicted which patients were likely to experience prolonged overall survival following VG161 treatment.[7] This finding represents a significant step towards a precision medicine approach for oncolytic virotherapy. If validated, this biomarker could be developed into a companion diagnostic to prospectively select patients most likely to benefit, thereby optimizing clinical outcomes and the efficiency of future clinical trials.

Table 2: Key Efficacy Results from the NCT04806464 Trial in Advanced HCC

The table below summarizes the key efficacy outcomes from the Phase I trial, highlighting the differential benefit based on prior CPI exposure and subsequent treatment.

Efficacy Endpoint	Overall HCC Population (n=35-40)	Subgroup: Prior CPI > 3 months (n=22)	Subgroup: Prior CPI ≤ 3 months	Subgroup: Received Post-VG161 Tx	Subgroup: No Post-VG161 Tx
ORR	17.1% - 18.9%	Data Not Specified	Data Not Specified	Data Not Specified	Data Not Specified
DCR	60.0% - 64.9%	Data Not Specified	Data Not Specified	Data Not Specified	Data Not Specified
Median PFS	2.9 months	Data Not Specified	Data Not Specified	Data Not Specified	Data Not Specified
Median OS	9.4 - 12.4 months	17.3 months	7.4 months	20.1 months	8.8 months
OS Hazard Ratio (HR)	N/A	0.32 (p<0.05) vs. Prior CPI ≤ 3m	N/A	0.30 (p<0.05) vs. No Post-Tx	N/A
Source(s)		8			9

4.3 Phase II Development (NCT05223816) and Combination with Nivolumab

Building on the success of the Phase I study, Virogin initiated a Phase IIa/IIb trial in the United States (NCT05223816), primarily conducted at the Mayo Clinic.[2] This open-label, multi-center study was designed to further evaluate the efficacy, safety, and tolerability of VG161 in patients with advanced HCC or ICC.[23] The trial, which is now closed to enrollment, featured a sophisticated design with a safety run-in cohort followed by expansion cohorts for both VG161 monotherapy and VG161 in combination with the PD-1 inhibitor nivolumab.[23]

The rationale for combining VG161 with a systemic checkpoint inhibitor like nivolumab is compelling. VG161's ability to turn "cold" tumors "hot" by promoting T-cell infiltration and upregulating immune activity is expected to create a more favorable TME for a systemic PD-1 inhibitor to exert its effect. This could lead to synergistic activity, resulting in deeper, more durable responses than could be achieved with either agent alone.

4.4 Combination Study with Camrelizumab (Phase Ib/IIa)

In China, a similar combination strategy is being explored in a Phase Ib/IIa study evaluating VG161 with camrelizumab, another PD-1 inhibitor, in patients with advanced HCC who have failed first-line therapy.[12]

Early results from this trial are encouraging. Among 11 evaluable participants, the combination yielded an ORR of 18.2% (2 partial responses) and stable disease in 8 additional patients. The median PFS was 6.3 months, and the 6-month OS rate was a promising 87.5%.[12] The combination was reported to have an acceptable safety profile, with the most common treatment-emergent adverse events (TEAEs) being fever (81.3%), reactive capillary hyperplasia (62.5%), hypoalbuminaemia (62.5%), and anaemia (62.5%).[12] These preliminary data further support the rationale for combining VG161 with checkpoint inhibitors.

5.0 Clinical Analysis: Sarcomas and Other Solid Tumors

While the most mature data for VG161 comes from liver cancer, Virogin is strategically expanding its development into other areas of high unmet need, most notably advanced sarcomas, where early clinical signals have been promising.

5.1 The Therapeutic Landscape and Unmet Need in Advanced Sarcomas

Soft tissue and bone sarcomas are a rare and heterogeneous group of malignancies.[32] For patients with advanced or metastatic disease that is not amenable to surgery, the prognosis is generally poor. The standard of care has long been cytotoxic chemotherapy, typically with doxorubicin-based regimens.[33] However, the efficacy of these treatments is limited, with median overall survival often in the range of only 8 to 12 months.[33] There is a clear and urgent need for novel therapeutic approaches that can offer improved outcomes for this patient population.[34]

5.2 Clinical Evidence in Sarcoma

The potential of VG161 in sarcoma was first highlighted in case reports from a Phase I dose-escalation trial conducted in Australia for patients with various advanced solid tumors.[10]

Phase I Case Reports

Two patients with advanced sarcoma who had exhausted all available standard therapies were treated with VG161 monotherapy. One patient had chondrosarcoma and the other had soft tissue sarcoma. While the best objective response achieved in both cases was stable disease, the clinically significant outcome was the duration of disease control. The patients experienced a "noteworthy prolongation of progression-free survival" of 11.8 months and 11.9 months, respectively.[10] In the context of advanced, refractory sarcoma where rapid progression is the norm, achieving nearly a year of disease stability represents a substantial clinical benefit. This suggests that for certain tumor types like sarcoma, traditional response criteria based on tumor shrinkage (ORR) may not fully capture the therapeutic benefit of an immunomodulatory agent like VG161. Instead, time-to-event endpoints such as PFS and OS may be more relevant measures of its efficacy. The treatment also led to clear pharmacodynamic evidence of anti-cancer immune activation in both blood and tumor samples, corroborating the drug's mechanism of action.[10]

Ongoing Phase II Trial (NCT06126510)

Based on these encouraging early signals, Virogin has initiated a dedicated Phase II clinical trial (NCT06126510) specifically for patients with advanced bone and soft tissue sarcoma.[35] The study, which is currently recruiting in China, aims to enroll 40 patients who have failed at least one line of standard treatment. It will further evaluate the efficacy and safety of VG161 monotherapy administered via intratumoral injection.[36] The results of this trial will be critical in establishing the role of VG161 in the treatment of sarcoma.

5.3 Emerging Data and Rationale in Other Malignancies

Virogin's development strategy includes exploring VG161's potential in other challenging solid tumors.

Gastric Cancer

A Phase Ib/IIa clinical study has been initiated to evaluate VG161 in combination with the PD-1 inhibitor nivolumab for patients with advanced metastatic gastric or gastroesophageal junction adenocarcinoma who have failed two or more prior systemic regimens.[37] This moves VG161 into another major gastrointestinal malignancy with significant unmet needs in later-line settings.

Pancreatic Cancer

While clinical trials have not yet been initiated, there is a strong preclinical rationale for investigating VG161 in pancreatic cancer. Studies in pancreatic cancer models have shown that VG161 can systematically activate both innate and acquired anti-tumor immunity and favorably remodel the notoriously dense and immunosuppressive tumor microenvironment of this disease.[19] These findings provide a solid theoretical foundation for future clinical applications in this highly lethal malignancy.

6.0 Consolidated Safety, Tolerability, and Pharmacologic Profile

A comprehensive assessment of VG161's safety, pharmacokinetic, and pharmacodynamic data from across its clinical program reveals a consistent, well-tolerated profile and provides direct evidence of its intended biological mechanisms.

6.1 Safety and Tolerability Across Clinical Trials

Data consolidated from Phase I and II trials in HCC, sarcoma, and other solid tumors demonstrate that VG161 has a consistent and manageable safety profile.[9]

The most common treatment-related adverse event (TRAE) observed is pyrexia (fever), which has been reported in a high percentage of patients, including 100% of an early HCC cohort and 81.3% in a combination study with camrelizumab.[12] This is an expected on-target effect, reflecting the acute inflammatory response triggered by the viral infection and cytokine release. Importantly, this fever is typically low-grade (Grade 1 or 2) and resolves promptly with standard symptomatic treatment.[9] Other frequently reported TRAEs include transient cytopenias (such as decreased lymphocyte counts), hypoalbuminaemia, and anaemia.[12]

A critical aspect of VG161's safety profile is the consistent absence of dose-limiting toxicities (DLTs) in the dose-escalation portions of the trials. The maximum tolerated dose (MTD) was not reached, indicating a high therapeutic index and allowing for the selection of a biologically active recommended Phase II dose (RP2D) without being constrained by toxicity.[8] This favorable tolerability is a key advantage, particularly when considering its use in combination with other systemic therapies.

Table 3: Comparative Safety Profile of VG161 vs. First-Line SoC in Advanced HCC

To contextualize the clinical tolerability of VG161, the following table compares its known adverse event profile with that of the current first-line standards of care in advanced HCC. This comparison highlights the potentially distinct and more manageable safety profile of VG161, which could be a significant differentiator in clinical practice.

Adverse Event Type	VG161 Monotherapy (Grade ≥3)	Atezolizumab + Bevacizumab (Grade ≥3)	Sorafenib/Lenvatinib (Grade ≥3)
Pyrexia (Fever)	Frequent but typically low grade; Grade 3 reported but manageable	Infrequent	Infrequent
Cytopenias (e.g., Lymphopenia)	Reported (e.g., 43.8% in combo)	Infrequent	Infrequent
Hypertension	Not reported as a key AE	Common (Bevacizumab-related)	Common (Lenvatinib)
Bleeding Events (e.g., GI)	Not reported as a key AE	Significant risk (Bevacizumab-related)	Low risk
Hand-Foot Skin Reaction	Not applicable	Low risk	Common (Sorafenib)
Diarrhea	Not reported as a key AE	Common	Common
Immune-Related AEs (e.g., colitis, hepatitis)	Low incidence reported	Present (Atezolizumab-related)	Not applicable
Source(s)		9

6.2 Pharmacokinetic (PK) Profile

Pharmacokinetic studies have been integral to the clinical trials, utilizing quantitative PCR (qPCR) to measure viral DNA and assess the distribution and replication of VG161.[13] The results confirm the intended localized nature of the therapy.

Following intratumoral injection, dose-dependent increases in VG161 DNA copy numbers have been detected in biopsies of the injected tumors, confirming successful viral delivery and robust replication at the site of disease.[40] In contrast, viral DNA has remained largely undetectable in systemic samples such as blood and urine.[13] This lack of systemic viremia is a key safety feature, indicating that the attenuated virus does not spread uncontrollably throughout the body. Viral shedding has been minimal, with some transient, low-level detection in swabs of the injection site, but not in oral swabs, and it resolves quickly.[40] Collectively, the PK data provide strong evidence that VG161's activity is effectively contained within the tumor, supporting its favorable safety profile.

6.3 Pharmacodynamic (PD) Profile

Pharmacodynamic analyses have provided direct evidence that VG161 engages its intended biological targets and successfully modulates the immune system both systemically and locally within the TME.

Systemic Cytokine Induction

Blood sample analysis has demonstrated that intratumoral injection of VG161 leads to a rapid and significant systemic increase in key immune-activating cytokines. Dose-dependent surges in IFN-γ, TNF-α, IL-12, and IL-15 have been observed post-treatment.[40] The most dramatic effect was seen with IFN-

γ, which increased by as much as 638-fold over baseline levels in one cohort.[41] This powerful IFN-

γ response is a hallmark of a Th1-polarized anti-tumor immune activation and serves as a potent systemic biomarker of the drug's biological activity.

Immune Cell Infiltration and TME Remodeling

Direct analysis of tumor biopsies taken before and after VG161 treatment has provided mechanistic proof of TME remodeling. Techniques such as single-cell RNA sequencing and multiplex immunofluorescence have revealed significant changes in the tumor's immune landscape.[5] Post-treatment samples show increased infiltration of effector immune cells, including CD8+ T cells and NK cells, along with a corresponding decrease in immunosuppressive T-regulatory cells.[7] Furthermore, analyses have shown the expansion of specific T-cell clonotypes, indicating that VG161 promotes a targeted, antigen-specific immune response against the tumor.[5] These findings are the cellular-level confirmation of the "cold-to-hot" tumor transition.

A particularly important pharmacodynamic finding is the observed upregulation of PD-L1 expression on cells within the TME following VG161 treatment.[40] This is not a sign of treatment failure but rather a mechanism of adaptive immune resistance. The potent IFN-

γ response stimulated by VG161 can induce tumor cells and other cells in the microenvironment to express more PD-L1 as a feedback mechanism to try and shut down the T-cell attack. This observation provides a powerful, data-driven biological rationale for the ongoing clinical trials combining VG161 with PD-1/PD-L1 checkpoint inhibitors. The combination is not merely additive; it is truly synergistic. VG161 first creates an inflamed, T-cell-rich environment and, in doing so, exposes a new vulnerability (increased PD-L1 expression) that can then be effectively targeted by a co-administered checkpoint inhibitor, leading to a more profound and durable anti-tumor response.

7.0 Corporate, Regulatory, and Market Context

The development of VG161 is underpinned by a robust corporate strategy, a series of positive regulatory interactions, and a favorable market landscape for innovative immuno-oncology therapies.

7.1 Developer Profile: Virogin Biotech

Virogin Biotech, founded in Vancouver, Canada, in 2015, is a privately held, clinical-stage biotechnology company with a sharp focus on next-generation immuno-oncology.[15] The company has established a global operational footprint with research and development hubs in Canada and China, and a US entity, Virogin USA, established in 2022.[1]

Virogin's corporate strategy is built upon two complementary and potentially synergistic technology platforms: a next-generation oncolytic HSV-1 virus platform and an mRNA vaccine and therapeutics platform.[15] This dual-platform approach is highly strategic. Beyond developing assets from each platform independently, the company is pioneering a "prime-boost" strategy. This approach envisions using an mRNA vaccine to "prime" a systemic, tumor-antigen-specific T-cell response, which is then "boosted" by an oncolytic virus like VG161 that disrupts the immunosuppressive TME, allowing the primed T-cells to effectively attack the tumor.[15] This forward-thinking strategy positions Virogin to develop proprietary, in-house combination therapies that could overcome the limitations of standalone treatments.

The company has demonstrated strong investor confidence, successfully raising substantial capital through multiple financing rounds. This includes a $62 million Series C financing in 2020 and a $127 million Series D2 financing in 2021, bringing total capital raised over a 15-month period to over $270 million.[45] This robust financial backing from a syndicate of prominent investors, including CDH Investments, Panlin Capital, and China Life Healthcare, has enabled the rapid advancement of its clinical and preclinical programs.[45] As a private entity, Virogin Biotech does not have public SEC filings; searches for the company returned filings for Vir Biotechnology, Inc. (NASDAQ: VIR), which is a separate and unaffiliated public company.[48]

Beyond its lead asset VG161, Virogin's pipeline includes VG201, a second-generation oncolytic virus built on a novel transcription-translation dual-regulation (TTDR) backbone designed for enhanced tumor-specific oncolytic activity, which is also in Phase I clinical trials.[17] The preclinical mRNA pipeline is also advancing, with candidates for infectious diseases like Monkeypox and cancer vaccines targeting HPV, HER2, and EBV.[1]

7.2 Global Regulatory Strategy and Milestones

VG161 has achieved several key regulatory milestones that validate its clinical potential and are designed to accelerate its development and review process in major global markets. This reflects an intelligently bifurcated global strategy, pursuing parallel expedited pathways in both the United States and China.

In the U.S., VG161 has received two important designations from the FDA:

• Fast Track Designation was granted in June 2023 for the treatment of patients with advanced, unresectable HCC who have failed standard therapies.[15] This designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.
• Orphan Drug Designation was granted in February 2023 for the treatment of intrahepatic cholangiocarcinoma (ICC).[15] This provides significant incentives for development, including potential market exclusivity for seven years upon approval, tax credits for clinical trials, and exemption from user fees.

In China, VG161 received Breakthrough Therapy Designation (BTD) from the Center for Drug Evaluation (CDE) of the NMPA in September 2024 for the treatment of advanced HCC.[15] This designation, based on the promising clinical data from the Phase I trial in China, is analogous to the FDA's BTD and is designed to expedite the development and review of innovative drugs for serious diseases.

This dual-track approach, securing expedited designations in the world's two largest pharmaceutical markets while leveraging a local partner in China, maximizes the global commercial potential of VG161 and de-risks its development path.

7.3 Market Landscape for Oncolytic Virotherapies

VG161 is entering a dynamic and rapidly growing segment of the oncology market. The global oncolytic virus immunotherapy market is projected to experience substantial growth over the next decade. Market size estimates for 2023-2024 range from $156.8 million to $306.2 million, with forecasted growth at a compound annual growth rate (CAGR) of between 18.3% and 26.4%.[51] Projections for the market value by 2030-2032 range from approximately $429 million to $1.9 billion, indicating a field with significant commercial potential.[51]

This growth is propelled by several key drivers: the continuously rising global incidence of cancer, an increasing scientific and clinical focus on combination therapies, significant advancements in genetic and viral engineering, and a more favorable regulatory environment for novel immunotherapies.[51]

In this competitive landscape, VG161 is well-positioned. The first oncolytic virus to gain FDA approval, talimogene laherparepvec (T-VEC, Imlygic), carries only a single payload (GM-CSF) and has seen modest commercial success, primarily in melanoma. VG161's sophisticated, multi-armed design represents a clear next-generation approach, engineered for a more potent and multi-faceted immune response intended to overcome the limitations of earlier agents. Its primary competition will come from other next-generation oncolytic viruses currently in clinical development. However, VG161's advanced clinical data and strong proof-of-concept in HCC, an area of huge unmet need, could provide it with a significant first-mover advantage in this major indication.

8.0 Synthesis, Strategic Recommendations, and Future Outlook

VG161 has emerged as a highly promising, next-generation oncolytic virotherapy with a differentiated mechanism of action and compelling early clinical data in some of the most challenging solid tumors. Its strategic development positions it to potentially address critical unmet needs in the evolving landscape of cancer immunotherapy.

8.1 Synthesis of VG161's Value Proposition (SWOT Analysis)

A strategic analysis of VG161 reveals a distinct profile of strengths, weaknesses, opportunities, and threats.

• Strengths:
• Sophisticated Multi-Payload Design: The "four-in-one" payload of IL-12, IL-15/IL-15Rα, and a PD-L1 blocker represents a state-of-the-art approach designed to attack multiple immune escape pathways simultaneously.
• Strong Clinical Efficacy in Refractory HCC: The demonstration of a meaningful survival benefit (9.4-12.4 months median OS) in a heavily pre-treated, post-CPI HCC population is a major strength.
• Immune Re-sensitization Capability: The most significant value proposition is its demonstrated ability to reverse acquired resistance to checkpoint inhibitors, offering a profound survival benefit (17.3 months median OS) in this key patient subgroup.
• Favorable Safety Profile: The therapy is well-tolerated, with manageable adverse events (primarily fever) and no DLTs reported, suggesting a wide therapeutic window and suitability for combination regimens.
• Expedited Regulatory Designations: Receiving Fast Track, Orphan Drug, and Breakthrough Therapy designations from the FDA and NMPA validates the clinical data and accelerates the path to market.
• Weaknesses:
• Intratumoral Administration: The current formulation requires direct intratumoral injection, which can be technically challenging or infeasible for patients with deep, inaccessible, or numerous small metastatic lesions.
• Potential for Neutralizing Antibodies: As with any viral therapy, there is a theoretical risk that pre-existing or treatment-induced anti-HSV-1 antibodies could limit efficacy upon repeated dosing, although this has not been reported as a significant clinical issue to date.
• Predictive Biomarker Requires Validation: The promising predictive gene signature is currently an exploratory finding and requires rigorous prospective validation before it can be used for patient selection in clinical practice.
• Opportunities:
• Address Major Unmet Need: VG161 has the potential to become a standard of care in second- or third-line HCC for the large and growing population of patients failing first-line CPIs.
• Expansion into Other Tumors: Promising early signals in sarcoma and a strong preclinical rationale in pancreatic cancer create significant opportunities for label expansion into other difficult-to-treat malignancies.
• Synergistic Combinations: The strong biological rationale for combining VG161 with systemic checkpoint inhibitors creates a clear path for its integration into current treatment paradigms.
• Companion Diagnostic Development: The predictive gene signature offers a clear opportunity to develop a companion diagnostic, enabling a precision medicine approach that would enhance efficacy rates and strengthen its value proposition.
• Threats:
• Competitive Landscape: The immuno-oncology field is highly competitive, with numerous novel therapies and other next-generation oncolytic viruses in development.
• Manufacturing and Scalability: The manufacturing of complex biological products like oncolytic viruses can present technical and logistical challenges, potentially impacting cost of goods and supply.
• Reimbursement and Market Access: As a novel, high-cost therapy, VG161 will likely face pricing and reimbursement hurdles that will need to be addressed with a strong health-economic value argument.

8.2 Key Unanswered Questions and Future Development Trajectory

While the data to date are highly encouraging, several key questions must be addressed as the VG161 program advances towards pivotal trials and potential commercialization.

• Prospective Validation of the Predictive Gene Signature: The most critical near-term objective should be the design and execution of a study to prospectively validate the gene signature identified in the Phase I HCC trial. Confirming its ability to enrich for responders would be a transformative step for the program.
• Optimization of Combination Strategies: Further investigation is needed to determine the optimal sequencing and timing of VG161 with CPIs. While the data strongly support its use after CPI failure, studies evaluating concurrent administration in earlier lines of therapy will be important for maximizing its potential.
• Development of Systemic Administration: The greatest limitation of the current formulation is its intratumoral delivery. The long-term trajectory for Virogin's platform should include the development of a systemically (intravenously) administered oncolytic virus. An IV-capable virus would dramatically broaden the eligible patient population to include those with widespread metastatic disease.
• Confirmation of Durability: Long-term follow-up from the ongoing Phase II trials is essential. Confirming that the observed responses and survival benefits are durable over several years will be crucial for establishing VG161 as a practice-changing therapy.

8.3 Concluding Assessment and Commercial Potential

In conclusion, VG161 is not merely an incremental advance in oncolytic virotherapy; it is a sophisticated, multi-mechanistic immunotherapy that has produced compelling and differentiated clinical results. Its unique ability to remodel the tumor microenvironment and, most critically, to reverse acquired resistance to checkpoint inhibitors in advanced hepatocellular carcinoma, positions it as a potential game-changer in oncology.

The therapy has demonstrated a favorable risk-benefit profile, with significant efficacy signals in a population with few to no options, coupled with a manageable safety profile. If the highly promising data from early-phase trials are replicated in pivotal studies, VG161 has a clear path to becoming a standard of care for post-immunotherapy HCC. The successful validation of its predictive biomarker would further solidify its position as a best-in-class agent, heralding a new era of precision oncolytic virotherapy. With a strong corporate strategy, significant financial backing, and a clear development path in other high-need indications like sarcoma, VG161 has substantial commercial potential. Its ultimate success will depend on continued positive clinical data, skillful navigation of the final stages of regulatory review, and a market access strategy that effectively communicates its unique value in overcoming one of the greatest challenges in modern cancer treatment: immunotherapy resistance.

Works cited

1. VG-161 by Virogin Biotech for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval - Pharmaceutical Technology, accessed September 8, 2025, https://www.pharmaceutical-technology.com/data-insights/vg-161-virogin-biotech-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/
2. VG161 - Virogin, accessed September 8, 2025, https://virogin.com/vg161/
3. VG161: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 8, 2025, https://go.drugbank.com/drugs/DB18469
4. Virogin Biotech Ltd. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed September 8, 2025, https://synapse.patsnap.com/organization/0bd7198d3a053cb6f497a5beef1b0e28
5. (PDF) Oncolytic virus VG161 offers new hope for refractory liver cancer - ResearchGate, accessed September 8, 2025, https://www.researchgate.net/publication/393611802_Oncolytic_virus_VG161_offers_new_hope_for_refractory_liver_cancer
6. Definition of oncolytic HSV-1-expressing IL-12, IL-15/IL-15-receptor alpha and PD-L1-blocking peptide VG161 - NCI Drug Dictionary, accessed September 8, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/804954
7. Oncolytic virus VG161 in refractory hepatocellular carcinoma, accessed September 8, 2025, https://www.researchgate.net/publication/389991615_Oncolytic_virus_VG161_in_refractory_hepatocellular_carcinoma
8. Groundbreaking research on CNBG-Virogin's oncolytic virus VG161 for advanced hepatocellular carcinoma published in prestigious Nature journal - Sinopharm, accessed September 8, 2025, http://en.sinopharm.com/2025-03/27/c_20019.htm
9. Clinical outcomes from a phase I clinical trial of a novel oncolytic ..., accessed September 8, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4105
10. Oncolytic virotherapy stimulates anti‑tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/38638849/
11. Oncolytic virotherapy stimulates anti‑tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11024735/
12. Oncolytic virus VG161 in combination with camrelizumab as second-line therapy in patients with advanced primary hepatocellular carcinoma: A phase Ib/IIa clinical study. - ASCO Publications, accessed September 8, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.e14605
13. 694 An open-label phase I dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of VG161 in patients with advanced primary liver cancer, accessed September 8, 2025, https://jitc.bmj.com/content/10/Suppl_2/A725
14. Oncolytic virus VG161 in refractory hepatocellular carcinoma - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/40108464/
15. Breaking News | Virogin's First Oncolytic Virus VG161 Receives ..., accessed September 8, 2025, https://virogin.com/breaking-news-virogins-first-oncolytic-virus-vg161-receives-breakthrough-therapy-designation-in-china/
16. VIROGIN Receives FDA Fast Track Designation for VG161, a Novel Therapy Candidate for the Treatment of Advanced Hepatocellular Carcinoma, accessed September 8, 2025, https://virogin.com/virogin-receives-fda-fast-track-designation-for-vg161-a-novel-therapy-candidate-for-the-treatment-of-advanced-hepatocellular-carcinoma/
17. Virogin Biotech Announces Dosing the First US Patient in a Phase 1 Study of VG201 for Patients With Advanced Solid Tumors - Life Sciences British Columbia, accessed September 8, 2025, https://lifesciencesbc.ca/members/virogin-biotech-announces-dosing-the-first-us-patient-in-a-phase-1-study-of-vg201-for-patients-with-advanced-solid-tumors/
18. Oncolytic virus VG161 offers new hope for refractory liver cancer - PMC, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12289480/
19. VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes - Consensus, accessed September 8, 2025, https://www.consensus.app/papers/vg161-activates-systemic-antitumor-immunity-in-ding-liang/1988b3ed75a650a08bbd6f3eb553bcb6/
20. www.zju.edu.cn, accessed September 8, 2025, https://www.zju.edu.cn/english/2025/0421/c19573a3040853/page.htm#:~:text=The%20VG161%20viruses%20profoundly%20activate,cancer%20cells%20in%20the%20meantime.
21. Virogin Biotech Archives - The Cancer Letter, accessed September 8, 2025, https://cancerletter.com/tag/virogin-biotech/
22. MD Anderson and Virogin Biotech announce strategic collaboration to accelerate oncolytic virus research and development for treating advanced cancers, accessed September 8, 2025, https://www.mdanderson.org/newsroom/md-anderson-and-virogin-biotech-announce-strategic-collaboration.h00-159542901.html
23. An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma - CenterWatch, accessed September 8, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT05223816/an-open-label-multiple-center-phase-iia-iib-clinical-trial-to-evaluate-the-efficacy-safety-and-tolerability-of-vg161-as-monotherapy-and-in-combination-with-nivolumab-for-treatment-of-patients-with-hepatocellular-carcinoma-or-intrahepatic-cholangiocarcinoma
24. Systemic Therapy for Advanced Hepatocellular Carcinoma: Current ..., accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10046570/
25. Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC) - PMC, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9075739/
26. Guideline Update Seeks to Aid Clinicians in the Selection of Systemic Treatments for Advanced Hepatocellular Carcinoma - The ASCO Post, accessed September 8, 2025, https://ascopost.com/issues/june-10-2024/guideline-update-seeks-to-aid-clinicians-in-the-selection-of-systemic-treatments-for-advanced-hepatocellular-carcinoma/
27. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline, accessed September 8, 2025, https://ascopubs.org/doi/10.1200/JCO.20.02672
28. VG161 Granted for FDA Orphan Drug Designation - Life Sciences British Columbia, accessed September 8, 2025, https://lifesciencesbc.ca/members/vg161-granted-for-fda-orphan-drug-designation/
29. New Options for Systemic Therapies in Intrahepatic ... - MDPI, accessed September 8, 2025, https://www.mdpi.com/1648-9144/59/6/1174
30. Management of intrahepatic cholangiocarcinoma: a review for clinicians - Oxford Academic, accessed September 8, 2025, https://academic.oup.com/gastro/article/doi/10.1093/gastro/goaf005/7979381
31. VG161 in the Treatment of Patients With Hepatocellular Carcinoma ..., accessed September 8, 2025, https://www.mayo.edu/research/clinical-trials/cls-20540752
32. NCCN Guidelines for Patients: Soft Tissue Sarcoma, accessed September 8, 2025, https://www.nccn.org/patients/guidelines/content/PDF/sarcoma-patient.pdf
33. Systemic Therapy for Advanced Soft Tissue Sarcomas - PMC, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3412982/
34. Treatment of Soft Tissue Sarcomas, by Stage | American Cancer Society, accessed September 8, 2025, https://www.cancer.org/cancer/types/soft-tissue-sarcoma/treating/by-stage.html
35. VG161 Recruiting Phase 2 Trials for Sarcomas Treatment | DrugBank Online, accessed September 8, 2025, https://go.drugbank.com/drugs/DB18469/clinical_trials?conditions=DBCOND0041813&phase=2&purpose=treatment&status=recruiting
36. Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma, accessed September 8, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06126510/clinical-study-of-vg161-in-the-treatment-of-advanced-bone-and-soft-tissue-sarcoma
37. Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer - TrialX, accessed September 8, 2025, https://www.trialx.com/clinical-trials/listings/261742/clinical-study-of-vg161-combined-with-nivolumab-injection-in-patients-with-advanced-metastatic-gastric-cancer/
38. VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/36042555/
39. VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes - PMC, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10087349/
40. Oncolytic virotherapy stimulates anti‑tumor immune response and ..., accessed September 8, 2025, https://researchnow.flinders.edu.au/files/125401107/Qiu_Oncolytic_P2024.pdf
41. Initial results from a first in human trial incorporating accelerated dose titration of a novel immune stimulating oncolytic virus - VG161. - ASCO, accessed September 8, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT336495
42. Virogin Announces Collaboration of Second-Generation VG201 with Akeso's AK112 for Colorectal Cancer Liver Metastasis, accessed September 8, 2025, https://virogin.com/virogin-announces-collaboration-of-second-generation-vg201-with-akesos-ak112-for-colorectal-cancer-liver-metastasis/
43. Virogin Secures Oral Presentation at ESMO 2024 with New Clinical Data on VG201, accessed September 8, 2025, https://virogin.com/virogin-secures-oral-presentation-at-esmo-2024-with-new-clinical-data-on-vg201/
44. About - Virogin Biotech, accessed September 8, 2025, https://virogin.com/about/
45. Virogin Biotech Announces Closing of $127 Million in Series D2 Financing, accessed September 8, 2025, https://lifesciencesbc.ca/members/virogin-biotech-announces-closing-of-127-million-in-series-d2-financing/
46. Virogin Biotech Announces Completion of $62 Million in Series C Financing - Life Sciences British Columbia, accessed September 8, 2025, https://lifesciencesbc.ca/members/virogin-biotech-announces-completion-of-62-million-in-series-c-financing/
47. Virogin Biotech transmits $62m series C -, accessed September 8, 2025, https://globalventuring.com/virogin-biotech-transmits-62m-series-c/
48. Vir Biotechnology, Inc. - Investor Relations, accessed September 8, 2025, https://investors.vir.bio/overview/default.aspx
49. Financials - SEC Filings - Vir Biotechnology, Inc. - Investor Relations, accessed September 8, 2025, https://investors.vir.bio/financials/sec-filings/default.aspx
50. Vir Biotechnology, Inc. Common Stock (VIR) SEC Filings - Nasdaq, accessed September 8, 2025, https://www.nasdaq.com/market-activity/stocks/vir/sec-filings
51. Press Release Service: Oncolytic Virus Immunotherapy Strategic Research Business Report 2025-2030: Surge in Clinical Trials Combining Oncolytic Viruses With Checkpoint Inhibitors Expands Therapeutic Horizons - ResearchAndMarkets.com - CRISPR Medicine News, accessed September 8, 2025, https://crisprmedicinenews.com/press-release-service/card/oncolytic-virus-immunotherapy-strategic-research-business-report-2025-2030-surge-in-clinical-trials/
52. Oncolytic Virotherapy Market Size And Share Report, 2030 - Grand View Research, accessed September 8, 2025, https://www.grandviewresearch.com/industry-analysis/oncolytic-virotherapy-market-report
53. Oncolytic Virus Immunotherapy Market: Trends Report, 2032, accessed September 8, 2025, https://www.gminsights.com/industry-analysis/oncolytic-virus-immunotherapy-market